Differential promoter methylation of kinesin family member 1a in plasma is associated with breast cancer and DNA repair capacity

Guerrero-Preston,Rafael; Hadar,Tal; Ostrow,Kimberly  Laskie; Soudry,Ethan; Echenique,Miguel; Ili-Gangas,Carmen; Pérez,Gabriela; Perez,Jimena; Brebi-Mieville,Priscilla; Deschamps,José; Morales,Luisa; Bayona,Manuel; Sidransky,David; Matta,Jaime

doi:10.3892/or.2014.3262

Differential promoter methylation of kinesin family member 1a in plasma is associated with breast cancer and DNA repair capacity

Authors:
- Rafael Guerrero-Preston
- Tal Hadar
- Kimberly Laskie Ostrow
- Ethan Soudry
- Miguel Echenique
- Carmen Ili-Gangas
- Gabriela Pérez
- Jimena Perez
- Priscilla Brebi-Mieville
- José Deschamps
- Luisa Morales
- Manuel Bayona
- David Sidransky
- Jaime Matta
View Affiliations

Affiliations: Department of Otolaryngology - Head and Neck Cancer Research Division, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA, Cancer Center, Auxilio Mutuo Hospital, San Juan, Puerto Rico, Department of Pharmacology and Toxicology, Ponce School of Medicine and Health Sciences, Ponce 00732-7004, Puerto Rico, Public Health Program, Ponce School of Medicine and Health Sciences, Ponce 00732-7004, Puerto Rico
Published online on: June 13, 2014 https://doi.org/10.3892/or.2014.3262
Pages: 505-512
Copyright: © Guerrero-Preston et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Methylation alterations of CpG islands, CpG island shores and first exons are key events in the formation and progression of human cancer, and an increasing number of differentially methylated regions and genes have been identified in breast cancer. Recent studies of the breast cancer methylome using deep sequencing and microarray platforms are providing a novel insight on the different roles aberrant methylation plays in molecular subtypes of breast cancer. Accumulating evidence from a subset of studies suggests that promoter methylation of tumor-suppressor genes associated with breast cancer can be quantified in circulating DNA. However, there is a paucity of studies that examine the combined presence of genetic and epigenetic alterations associated with breast cancer using blood-based assays. Dysregulation of DNA repair capacity (DRC) is a genetic risk factor for breast cancer that has been measured in lymphocytes. We isolated plasma DNA from 340 participants in a breast cancer case control project to study promoter methylation levels of five genes previously shown to be associated with breast cancer in frozen tissue and in cell line DNA: MAL, KIF1A, FKBP4, VGF and OGDHL. Methylation of at least one gene was found in 49% of the cases compared to 20% of the controls. Three of the four genes had receiver characteristic operator curve values of ≥0.50: MAL (0.64), KIF1A (0.51) and OGDHL (0.53). KIF1A promoter methylation was associated with breast cancer and inversely associated with DRC. This is the first evidence of a significant association between genetic and epigenetic alterations in breast cancer using blood-based tests. The potential diagnostic utility of these biomarkers and their relevance for breast cancer risk prediction should be examined in larger cohorts.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
2	Forouzanfar MH, Foreman KJ, Delossantos AM, et al: Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet. 378:1461–1484. 2011. View Article : Google Scholar : PubMed/NCBI
3	Bray F, Ren JS, Masuyer E and Ferlay J: Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 132:1133–1145. 2013. View Article : Google Scholar : PubMed/NCBI
4	Figueroa-Vallés NR, Ortiz-Ortiz KJ, Pérez-Ríos N, Villanueva-Rosa E, Traverso-Ortiz M, Torres-Cintrón CR and Suárez-Ramos T: Cancer in Puerto Rico, 2004–2009. Puerto Rico Central Cancer Registry; San Juan: 2012
5	Gøtzsche PC: Mammography screening: truth, lies, and controversy. Lancet. 380:2182012.PubMed/NCBI
6	Ogino S, Lochhead P, Chan AT, et al: Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. Mod Pathol. 26:465–484. 2013. View Article : Google Scholar : PubMed/NCBI
7	Ostrow KL, Park HL, Hoque MO, et al: Pharmacologic unmasking of epigenetically silenced genes in breast cancer. Clin Cancer Res. 15:1184–1191. 2009. View Article : Google Scholar : PubMed/NCBI
8	Kim GE, Lee KH, Choi YD, et al: Detection of Slit2 promoter hypermethylation in tissue and serum samples from breast cancer patients. Virchows Arch. 459:383–390. 2011. View Article : Google Scholar : PubMed/NCBI
9	Ramos JM, Ruiz A, Colen R, Lopez ID, Grossman L and Matta JL: DNA repair and breast carcinoma susceptibility in women. Cancer. 100:1352–1357. 2004. View Article : Google Scholar : PubMed/NCBI
10	Matta JL, Villa JL, Ramos JM, et al: DNA repair and nonmelanoma skin cancer in Puerto Rican populations. J Am Acad Dermatol. 49:433–439. 2003. View Article : Google Scholar : PubMed/NCBI
11	Matta J, Echenique M, Negron E, et al: The association of DNA repair with breast cancer risk in women. A comparative observational study. BMC Cancer. 12:4902012. View Article : Google Scholar : PubMed/NCBI
12	Morales L, Alvarez-Garriga C, Matta J, et al: Factors associated with breast cancer in Puerto Rican women. J Epidemiol Glob Health. 3:205–215. 2013. View Article : Google Scholar : PubMed/NCBI
13	Hoque MO, Begum S, Topaloglu O, et al: Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst. 98:996–1004. 2006. View Article : Google Scholar : PubMed/NCBI
14	Rosner B: Fundamentals of Biostatistics. 7th edition. Brooks/Cole; Boston, MA: 2010
15	Szklo MNJ: Epidemiology Beyond the Basics. Jones and Bartlett Learning; Burlington, MA: 2006
16	Lo KY, Kuzmin A, Unger SM, Petersen JD and Silverman MA: KIF1A is the primary anterograde motor protein required for the axonal transport of dense-core vesicles in cultured hippocampal neurons. Neurosci Lett. 491:168–173. 2011. View Article : Google Scholar : PubMed/NCBI
17	Brait M, Loyo M, Rosenbaum E, et al: Correlation between BRAF mutation and promoter methylation of TIMP3, RARβ2 and RASSF1A in thyroid cancer. Epigenetics. 7:710–719. 2012.
18	Roh JL, Wang XV, Manola J, Sidransky D, Forastiere AA and Koch WM: Clinical correlates of promoter hypermethylation of four target genes in head and neck cancer: a cooperative group correlative study. Clin Cancer Res. 19:2528–2540. 2013. View Article : Google Scholar : PubMed/NCBI
19	Ostrow KL, Hoque MO, Loyo M, et al: Molecular analysis of plasma DNA for the early detection of lung cancer by quantitative methylation-specific PCR. Clin Cancer Res. 16:3463–3472. 2010. View Article : Google Scholar : PubMed/NCBI
20	Demokan S, Chang X, Chuang A, et al: KIF1A and EDNRB are differentially methylated in primary HNSCC and salivary rinses. Int J Cancer. 127:2351–2359. 2010. View Article : Google Scholar : PubMed/NCBI
21	De S, Cipriano R, Jackson MW and Stark GR: Overexpression of kinesins mediates docetaxel resistance in breast cancer cells. Cancer Res. 69:8035–8042. 2009. View Article : Google Scholar : PubMed/NCBI
22	Horne HN, Lee PS, Murphy SK, Alonso MA, Olson JA Jr and Marks JR: Inactivation of the MAL gene in breast cancer is a common event that predicts benefit from adjuvant chemotherapy. Mol Cancer Res. 7:199–209. 2009.
23	Suzuki M, Shiraishi K, Eguchi A, et al: Aberrant methylation of LINE-1, SLIT2, MAL and IGFBP7 in non-small cell lung cancer. Oncol Rep. 29:1308–1314. 2013.PubMed/NCBI
24	Lind GE, Danielsen SA, Ahlquist T, et al: Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas. Mol Cancer. 10:852011. View Article : Google Scholar : PubMed/NCBI
25	Galigniana MD, Harrell JM, O‘Hagen HM, Ljungman M and Pratt WB: Hsp90-binding immunophilins link p53 to dynein during p53 transport to the nucleus. J Biol Chem. 279:22483–22489. 2004. View Article : Google Scholar : PubMed/NCBI
26	Lin JF, Xu J, Tian HY, et al: Identification of candidate prostate cancer biomarkers in prostate needle biopsy specimens using proteomic analysis. Int J Cancer. 121:2596–2605. 2007. View Article : Google Scholar : PubMed/NCBI
27	Ward BK, Mark PJ, Ingram DM, Minchin RF and Ratajczak T: Expression of the estrogen receptor-associated immunophilins, cyclophilin 40 and FKBP52, in breast cancer. Breast Cancer Res Treat. 58:267–280. 1999.PubMed/NCBI
28	Levi A, Ferri GL, Watson E, Possenti R and Salton SR: Processing, distribution, and function of VGF, a neuronal and endocrine peptide precursor. Cell Mol Neurobiol. 24:517–533. 2004. View Article : Google Scholar : PubMed/NCBI
29	Ferri GL, Noli B, Brancia C, D‘Amato F and Cocco C: VGF: an inducible gene product, precursor of a diverse array of neuro-endocrine peptides and tissue-specific disease biomarkers. J Chem Neuroanat. 42:249–261. 2011. View Article : Google Scholar
30	Brait M, Maldonado L, Noordhuis MG, et al: Association of promoter methylation of VGF and PGP9.5 with ovarian cancer progression. PLoS One. 8:e708782013.PubMed/NCBI
31	Brait M, Maldonado L, Begum S, et al: DNA methylation profiles delineate epigenetic heterogeneity in seminoma and non-seminoma. Br J Cancer. 106:414–423. 2012. View Article : Google Scholar : PubMed/NCBI
32	Sen T, Sen N, Noordhuis MG, et al: OGDHL is a modifier of AKT-dependent signaling and NF-κB function. PLoS One. 7:e487702012.PubMed/NCBI
33	Lahtz C and Pfeifer GP: Epigenetic changes of DNA repair genes in cancer. J Mol Cell Biol. 3:51–58. 2011. View Article : Google Scholar : PubMed/NCBI
34	Leary AF, Castro DG, Nicholson AG, et al: Establishing an EGFR mutation screening service for non-small cell lung cancer - sample quality criteria and candidate histological predictors. Eur J Cancer. 48:61–67. 2012.
35	Silva JM, Dominguez G, Garcia JM, et al: Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations. Cancer Res. 59:3251–3256. 1999.PubMed/NCBI
36	Hoque MO, Feng Q, Toure P, et al: Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J Clin Oncol. 24:4262–4269. 2006. View Article : Google Scholar : PubMed/NCBI
37	Heichman KA and Warren JD: DNA methylation biomarkers and their utility for solid cancer diagnostics. Clin Chem Lab Med. 50:1707–1721. 2012. View Article : Google Scholar : PubMed/NCBI
38	Latimer JJ, Johnson JM, Kelly CM, et al: Nucleotide excision repair deficiency is intrinsic in sporadic stage I breast cancer. Proc Natl Acad Sci USA. 107:21725–21730. 2010. View Article : Google Scholar : PubMed/NCBI
39	Li L: Nucleotide excision repair. DNA Repair, Genetic Instability and Cancer. Wei Q, Lei L and Chen DJ: World Scientific; Singapore: pp. 65–86. 2007, View Article : Google Scholar
40	Berwick M and Vineis P: Measuring DNA repair capacity: small steps. J Natl Cancer Inst. 97:84–85. 2005. View Article : Google Scholar : PubMed/NCBI
41	Curtin N: PARP inhibitors for anticancer therapy. Biochem Soc Trans. 42:82–88. 2014. View Article : Google Scholar
42	Eccles SA, Aboagye EO, Ali S, et al: Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res. 15:R922013. View Article : Google Scholar : PubMed/NCBI
43	Glendenning J and Tutt A: PARP inhibitors - current status and the walk towards early breast cancer. Breast. 20(Suppl 3): S12–S19. 2011. View Article : Google Scholar : PubMed/NCBI